A portable RT-LAMP assay achieved a detection limit of 500 RNA copies for SFTSV, highlighting its potential for point-of-care testing.
Severe Fever with Thrombocytopenia Syndrome virus (SFTSV) is a tick-borne pathogen associated with high mortality, particularly among the elderly, and poses a significant public health threat in East Asia's rural areas. Improved diagnostic approaches are crucial for effective disease management in resource-limited settings. In this study, we developed a portable Reverse Transcription Loop-Mediated Isothermal Amplification (RT-LAMP) platform for rapid and accurate SFTSV detection. Primers targeting the conserved L gene were designed using 158 sequences collected between 2019 and 2023, and a multiplex assay incorporating the β-actin gene as an internal control to verify amplification efficiency in alignment with clinical performance requirements. We assessed the assay's sensitivity and specificity, ultimately establishing the RT-LAMP platform in a portable, clinical-grade device. The RT-LAMP assay achieved a detection limit of 500 RNA copies per reaction and provided results within 20 min. It demonstrated high specificity without cross-reactivity with other pathogens. Performance comparisons with commercial qRT-PCR kits using clinical specimens confirmed the RT-LAMP platform's reliability. The newly developed RT-LAMP platform is a rapid, accurate, and cost-effective diagnostic tool for SFTSV with strong potential for point-of-care testing (POCT). Its portability and ease of use make it ideal for application in resource-constrained environments, thereby enhancing SFTSV surveillance and improving public health outcomes in affected regions.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: